News headlines about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spero Therapeutics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.8421531133247 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Spero Therapeutics (SPRO) Presents At Needham And Company 17th Annual Healthcare Conference – Slideshow (seekingalpha.com)
- Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry (finance.yahoo.com)
- Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00 (americanbankingnews.com)
- -$1.56 EPS Expected for Spero Therapeutics Inc (SPRO) This Quarter (americanbankingnews.com)
- Spero Therapeutics Inc (SPRO) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
NASDAQ:SPRO opened at $14.25 on Friday. Spero Therapeutics has a 12 month low of $9.66 and a 12 month high of $15.40.
TRADEMARK VIOLATION WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/30/spero-therapeutics-spro-receives-daily-coverage-optimism-rating-of-0-04/1973817.html.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.